Confidence Region Approach for Assessing Bioequivalence and Biosimilarity Accounting for Heterogeneity of Variability
For approval of generic drugs, the FDA requires that evidence of bioequivalence in average bioequivalence in terms of drug absorption be provided through the conduct of a bioequivalence study. A test product is said to be average bioequivalent to a reference (innovative) product if the 90% confidenc...
Main Authors: | Jianghao Li, Shein-Chung Chow |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Journal of Probability and Statistics |
Online Access: | http://dx.doi.org/10.1155/2015/298647 |
Similar Items
-
Focus on biosimilar etanercept – bioequivalence and interchangeability
by: Cantini F, et al.
Published: (2018-08-01) -
Update on the safety and bioequivalence of biosimilars – focus on enoxaparin
by: Jeske W, et al.
Published: (2013-06-01) -
On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012-03-01) -
An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
by: Zhou X, et al.
Published: (2021-07-01) -
Statistical considerations of noninferiority, bioequivalence and equivalence testing in biosimilars studies
by: Xu, Siyan
Published: (2016)